Testing vancomycin for certain pediatric bile duct conditions
Treatments studied
Part of Digestive system, Genetic & congenital clinical trials.
This early-phase study tests whether the antibiotic vancomycin can help children with primary sclerosing cholangitis or biliary atresia, and related gut/bile duct problems. It may work by changing gut bacteria, but you would need to avoid certain medicines beforehand.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a diagnosis of primary sclerosing cholangitis, biliary atresia, or a related chronic intestinal condition, or be scheduled for an endoscopy
- If you specifically have primary sclerosing cholangitis or biliary atresia, your doctor must think vancomycin is a good match for you
- Have NOT taken antibiotics in the last 3 months (including course completion)
- Have NOT taken medicines that change the immune system (immunomodulators) in the last 3 months
- If you are pregnant, you cannot join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether the antibiotic vancomycin can improve primary sclerosing cholangitis (PSC), a long-term bile-duct disease. You may be eligible if you have confirmed PSC and certain blood test and safety criteria, and you can follow medication washout rules.
This study tests whether a treatment made from mouth bacteria can help people with primary sclerosing cholangitis (PSC). It aims to see if it's safe and improves health.
This trial studies whether giving oral antibiotics before symptoms start can lower the chance of cholangitis (bile duct infection/inflammation) after Kasai portoenterostomy. It may help protect your child’s bile flow and reduce painful or serious infections after surgery.
This study tests whether a specific antibiotic called vancomycin can help children with an unusual type of gut inflammation (colitis). The researchers believe an imbalance in gut bacteria may be causing the problem, and vancomycin might restore that balance.
This trial tests if vancomycin, an antibiotic, can reduce inflammation in people with both ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). It aims to see if the drug helps control disease activity in moderate to severe UC.
This Phase 1 study tests whether the antibiotic vancomycin can be given safely to people with newly diagnosed multiple sclerosis (or related early stages). It mainly focuses on safety and side effects, and whether the approach is feasible for this group.
Hear when a new Primary Sclerosing Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.